Flag Ship Acquisition (ETHZ) Competitors $2.53 +0.13 (+5.42%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ETHZ vs. COEP, IMMX, CVM, DRRX, NRXP, CELU, ALXO, ARTV, DTIL, and PRLDShould you be buying Flag Ship Acquisition stock or one of its competitors? The main competitors of Flag Ship Acquisition include Coeptis Therapeutics (COEP), Immix Biopharma (IMMX), CEL-SCI (CVM), DURECT (DRRX), NRx Pharmaceuticals (NRXP), Celularity (CELU), ALX Oncology (ALXO), Artiva Biotherapeutics (ARTV), Precision BioSciences (DTIL), and Prelude Therapeutics (PRLD). These companies are all part of the "pharmaceutical products" industry. Flag Ship Acquisition vs. Its Competitors Coeptis Therapeutics Immix Biopharma CEL-SCI DURECT NRx Pharmaceuticals Celularity ALX Oncology Artiva Biotherapeutics Precision BioSciences Prelude Therapeutics Flag Ship Acquisition (NASDAQ:ETHZ) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation. Which has better valuation and earnings, ETHZ or COEP? Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFlag Ship AcquisitionN/AN/A-$6.17M-$15.07-0.17Coeptis TherapeuticsN/AN/A-$10.88M-$5.80-3.08 Which has more risk & volatility, ETHZ or COEP? Flag Ship Acquisition has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.57, suggesting that its stock price is 157% less volatile than the S&P 500. Do insiders & institutionals believe in ETHZ or COEP? 4.1% of Flag Ship Acquisition shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 5.4% of Flag Ship Acquisition shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor ETHZ or COEP? In the previous week, Flag Ship Acquisition had 3 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for Flag Ship Acquisition and 1 mentions for Coeptis Therapeutics. Flag Ship Acquisition's average media sentiment score of 0.70 beat Coeptis Therapeutics' score of 0.00 indicating that Flag Ship Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Flag Ship Acquisition 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ETHZ or COEP more profitable? Flag Ship Acquisition's return on equity of -141.25% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Flag Ship AcquisitionN/A -141.25% -80.77% Coeptis Therapeutics N/A -201.73%-108.46% SummaryFlag Ship Acquisition beats Coeptis Therapeutics on 7 of the 10 factors compared between the two stocks. Get Flag Ship Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for ETHZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ETHZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ETHZ vs. The Competition Export to ExcelMetricFlag Ship AcquisitionPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$416.01M$872.83M$2.54B$10.43BDividend YieldN/A4.84%2.49%4.58%P/E Ratio-0.171.2026.5226.62Price / SalesN/A25.75107.75126.99Price / CashN/A17.6550.6131.15Price / Book0.876.4633.226.47Net Income-$6.17M-$5.56M$14.12M$271.57M7 Day Performance9.52%-0.58%0.72%2.83%1 Month PerformanceN/A5.73%3.70%7.27%1 Year PerformanceN/A23.86%17.52%26.09% Flag Ship Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ETHZFlag Ship AcquisitionN/A$2.53+5.4%N/AN/A$416.01MN/A-0.177News CoverageOptions VolumeGap UpCOEPCoeptis Therapeutics0.156 of 5 stars$13.88+10.6%N/A+337.2%$60.49MN/A-2.392News CoverageHigh Trading VolumeIMMXImmix Biopharma3.0904 of 5 stars$2.19+4.8%$8.00+265.3%+24.4%$60.26MN/A-2.849High Trading VolumeCVMCEL-SCI1.5291 of 5 stars$8.67-2.8%N/A-72.3%$59.67MN/A-18.0643Positive NewsDRRXDURECT1.6612 of 5 stars$1.91flatN/AN/A$59.31M$1.66M-19.1080NRXPNRx Pharmaceuticals2.5425 of 5 stars$2.97-0.3%$34.50+1,061.6%+76.1%$59.03MN/A-1.332Positive NewsCELUCelularity1.2982 of 5 stars$2.22+1.4%$6.00+170.3%-28.9%$58.45M$54.22M-0.70220High Trading VolumeALXOALX Oncology3.8117 of 5 stars$1.21+11.0%$3.30+172.7%-38.6%$58.37MN/A-0.5540Positive NewsHigh Trading VolumeARTVArtiva Biotherapeutics2.5351 of 5 stars$2.88+21.0%$17.00+490.3%-78.3%$58.13M$250K0.0081High Trading VolumeDTILPrecision BioSciences4.225 of 5 stars$4.78-2.6%$47.00+883.3%-49.4%$57.87M$68.70M-0.54200PRLDPrelude Therapeutics3.1057 of 5 stars$0.98-2.5%$4.00+306.2%-60.4%$57.17M$7M-0.60120News CoverageAnalyst ForecastGap Up Related Companies and Tools Related Companies Coeptis Therapeutics Competitors Immix Biopharma Competitors CEL-SCI Competitors DURECT Competitors NRx Pharmaceuticals Competitors Celularity Competitors ALX Oncology Competitors Artiva Biotherapeutics Competitors Precision BioSciences Competitors Prelude Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ETHZ) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flag Ship Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Flag Ship Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
